Výsledky vyhledávání - "Lyudmyla Derby Berim"

Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer

Autor: Howard S. Hochster, Hao Liu, Lyudmyla Derby Berim, Kristen Renee Spencer, Pat Gulhati, Manda DiRubbo, Seth D. Cohen, Patrick Lee, Stuart P. Leitner, Delia Radovich, Christian Misdary, Christian Perez, Sutirtha Datta, Andrea Gonzalez, Tracie Saunders, Patrick M Boland

Publikováno v: Journal of Clinical Oncology. 41:144-144

144 Background: TAS-102 (trifluridine/tipiracil) is a novel oral antimetabolite for late line metastatic colorectal cancer (CRC) approved in 2018. Many patients are treated early in their course with oxaliplatin (OX), particularly adjuvant, and may b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb95db16639d726f0274f8fccc089c3d
https://doi.org/10.1200/jco.2023.41.4_suppl.144

Zobrazit plný text záznamu

HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer—Preliminary efficacy and correlative results

Autor: Kristen Renee Spencer, Howard S. Hochster, Patrick M Boland, Lyudmyla Derby Berim, Timothy Kennedy, Miral Grandhi, Russell C Langan, Dirk F. Moore, Michael P. Kane, Smitha S. Krishnamurthi, Skye C. Mayo, Anup Kasi, Agustin Pimentel, Darren R. Carpizo

Publikováno v: Journal of Clinical Oncology. 41:103-103

103 Background: Novel strategies to improve the efficacy of immune checkpoint inhibitors in microsatellite stable (MSS) mCRC are needed. CV301 is a vector-based vaccine that expresses carcinoembryonic antigen (CEA) and mucin 1 (MUC1), and in a phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::616769a248a3a408df18a396542973ee
https://doi.org/10.1200/jco.2023.41.4_suppl.103

Zobrazit plný text záznamu

High-risk MSI-H stage II colon cancer: Treatment patterns and outcomes

Autor: Patrick Fleming, Chunxia Chen, Dirk F. Moore, Howard S. Hochster, Salma K. Jabbour, Lyudmyla Derby Berim, Kristen Renee Spencer, Pat Gulhati, Kristen Donohue, Nell Maloney Patel, Patrick M Boland

Publikováno v: Journal of Clinical Oncology. 40:e15587-e15587

e15587 Background: For resected stage II MSI-high (MSI-H) colorectal cancer (CRC) without high-risk features (HRF), standard of care recommendation per NCCN guidelines is observation. For tumors with HRF, the prognostic significance and impact of adj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b842d44f6f4cb0ebc63bf3fce692f125
https://doi.org/10.1200/jco.2022.40.16_suppl.e15587

Zobrazit plný text záznamu

Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE)

Autor: J. Randolph Hecht, Ardaman Shergill, Mark Gregory Goldstein, Bruno Fang, May Thet Cho, Heinz-Josef Lenz, Lyudmyla Derby Berim, Paul Eliezer Oberstein, Rachael A Safyan, Vivek Sawhney, Heloisa P. Soares, David R. Spigel, Alexander I. Spira, Andrew R. Ferguson, Brian Chauder, Alexander Starodub

Publikováno v: Journal of Clinical Oncology. 40:TPS3635-TPS3635

TPS3635 Background: Treatment options for most patients with metastatic colorectal cancer (mCRC) are largely limited to cytotoxic chemotherapy, with little advancement in the last decade. Encouragingly, a small subset of patients deficient in mismatc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0ff743a9d42e7eb5f7e1c0731bb39d2
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3635

Zobrazit plný text záznamu

A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma

Autor: Chandrakanth Are, Christopher F. Nicodemus, Madi Madiyalakan, Jane L. Meza, Jean L. Grem, Quan P. Ly, James K. Schwarz, Chi Lin, James C. Padussis, Michael A. Hollingsworth, Lyudmyla Derby Berim

Publikováno v: Journal of Clinical Oncology. 36:e16202-e16202

e16202Background: CA-125, a tumor marker expressed in > 50% pancreatic adenocarcinoma (PAC), was targeted with oregovomab (O), a monoclonal antibody currently in development as chemoimmunotherapy (...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42926182f26575a8ee01056a7303d49f
https://doi.org/10.1200/jco.2018.36.15_suppl.e16202

Zobrazit plný text záznamu

A phase I study of ADH-1 with cisplatin (Cisp) and gemcitabine (Gem) in patients (Pts) with unresectable or metastatic pancreatic and biliary tract cancers

Autor: Ruby Evande, Beth M Kos, James K. Schwarz, Jean L. Grem, Jane L. Meza, Lyudmyla Derby Berim, Valerie Shostrom

Publikováno v: Journal of Clinical Oncology. 35:306-306

306 Background: Pancreatic cancer cells in vitro undergo epithelial to mesenchymal transformation (EMT) by up-regulating mesenchymal markers, including N-cadherin. The EMT leads to increased motility & invasiveness with collagen exposure in a pancrea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40195c4d627ac3fc7f87d92cc697668c
https://doi.org/10.1200/jco.2017.35.4_suppl.306

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání